SUVENUpdated 2 Sept 2026, 0:03

Suven Life Sciences Ltd

SUVENUpdated 2 Sept 2026, 0:03

Market Cap

₹10,773Cr.

Current Price

₹382

High / Low

₹403/124

ROE-5.59%

ROCE-5.53%

Book Value₹57.0

Face Value₹1.00

Dividend Yield0.00%

About

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1][2]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jul 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	28	39	31	36	3	66	48	40	22	40	73	78
Inventory Days	165	183	222	329	0	—	—	—	—	—	—	—
Days Payable	89	78	91	134	—	—	—	—	—	—	—	—
Cash Conversion Cycle	105	144	162	231	3	66	48	40	22	40	73	78
Working Capital Days	49	60	45	85	56	1,181	1,265	281	443	375	427	768
ROCE %	31%	17%	19%	25%	7%	-6%	-7%	-9%	-4%	-2%	-6%	-6%

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 2 September 2026 at 0:03

SUVEN LIFE SCIENCES LTD (SUVEN) financials — quarterly results, P&L, cash flow, balance sheet, shareholding